Your session is about to expire
← Back to Search
Dual Mobility System
Primary Total Hip Arthroplasty (THA) for Hip Revision Surgery (OR3O Trial)
N/A
Recruiting
Led By Ran Schwarzkopf, MD
Research Sponsored by Smith & Nephew, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks, 1 year, 2 years, 5 years, and 10 years
Awards & highlights
Summary
The purpose of this study is to assess the safety and effectiveness of the OR3O™ Dual Mobility System. The study will evaluate the outcome of the Total Hip Arthroplasty using the OR3O™ Dual Mobility System over a ten year period. Survivorship of THA will be assessed up to ten years.
Eligible Conditions
- Hip Revision Surgery
- Hip Osteoarthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 weeks, 1 year, 2 years, 5 years, and 10 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks, 1 year, 2 years, 5 years, and 10 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Survivorship of Primary Total Hip Arthroplasty (THA)
Secondary outcome measures
Five-level EuroQol five-dimensional (EQ-5D-5L) score
Forgotten Joint Score 12 (FJS-12)
Harris Hip Score (HHS)
+13 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Revision Total Hip Arthroplasty (THA)Experimental Treatment1 Intervention
OR3O Dual Mobility System used in revision THA
Group II: Primary Total Hip Arthroplasty (THA)Experimental Treatment1 Intervention
OR3O Dual Mobility System used in primary THA
Find a Location
Who is running the clinical trial?
Smith & Nephew, Inc.Lead Sponsor
167 Previous Clinical Trials
21,931 Total Patients Enrolled
Ran Schwarzkopf, MDPrincipal InvestigatorNYU Langone Health
4 Previous Clinical Trials
2,490 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger